Butyl(thiophen-2-ylmethyl)carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: Butyl(thiophen-2-ylmethyl)carbamic acid
• 英文别名: butyl(thiophen-2-ylmethyl)carbamic acid
• 化学式: C₁₀H₁₅NO₂S
• 分子量: 213.3
• InChiKey: AIRBJINEBYGVJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  68.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Texas Heart Institute

  公开号：EP2640721B1

  公开（公告）日：2018-06-06
• Agonists that enhance binding of integrin-expressing cells to integrin receptors
  申请人：Texas Heart Institute

  公开号：EP2881393B1

  公开（公告）日：2018-06-06
• NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS
  申请人：7 HILLS INTERESTS, LLC

  公开号：EP3288585A2

  公开（公告）日：2018-03-07
• [EN] NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS<br/>[FR] NOUVELLES COMPOSITIONS ET MÉTHODES POUR IMMUNOTHÉRAPIES COMPRENANT DES ADJUVANTS AGONISTES DES RÉCEPTEURS-LIGANDS D'INTÉGRINE À PETITES MOLÉCULES
  申请人：7 HILLS INTERESTS LLC

  公开号：WO2016176400A2

  公开（公告）日：2016-11-03

  Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which maybe used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to ϒδΤ-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti- CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).